Literature DB >> 18320148

Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide-dexamethasone.

Francesca Magalini, Adriano Stella, Paolo Sansoni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18320148     DOI： 10.1007/s11739-008-0136-0

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  12 in total

1.  The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64.

Authors:  Desmond A McCarthy; Marion G Macey; Matthew Streetly; Stephen A Schey; K Alun Brown
Journal:  Int Immunopharmacol       Date:  2006-03-29       Impact factor: 4.932

2.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  S Vincent Rajkumar; Emily Blood; David Vesole; Rafael Fonseca; Philip R Greipp
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

3.  Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

Authors:  Michele Cavo; Elena Zamagni; Patrizia Tosi; Paola Tacchetti; Claudia Cellini; Delia Cangini; Antonio de Vivo; Nicoletta Testoni; Chiara Nicci; Carolina Terragna; Tiziana Grafone; Giulia Perrone; Michela Ceccolini; Sante Tura; Michele Baccarani
Journal:  Blood       Date:  2005-03-10       Impact factor: 22.113

4.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Edie Weller; Teru Hideshima; Constantine Mitsiades; Faith Davies; Richard LeBlanc; Laurence P Catley; Deborah Doss; Kathleen Kelly; Mary McKenney; Julie Mechlowicz; Andrea Freeman; Reggie Deocampo; Rebecca Rich; Joan J Ryoo; Dharminder Chauhan; Kathe Balinski; Jerome Zeldis; Kenneth C Anderson
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

5.  Antitumor activity of thalidomide in refractory multiple myeloma.

Authors:  S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

6.  Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.

Authors:  Serena Mazzotta; Alessandro Gozzetti; Maria Teresa Pirrotta; Monica Bocchia; Simona Sammassimo; Alessandro Bucalossi; Francesco Lauria
Journal:  Leuk Lymphoma       Date:  2005-12

Review 7.  Thalidomide and dexamethasone: therapy for multiple myeloma.

Authors:  Shaji Kumar; S Vincent Rajkumar
Journal:  Expert Rev Anticancer Ther       Date:  2005-10       Impact factor: 4.512

8.  First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.

Authors:  Michele Cavo; Elena Zamagni; Patrizia Tosi; Claudia Cellini; Delia Cangini; Paola Tacchetti; Nicoletta Testoni; Michela Tonelli; Antonio de Vivo; Gualtiero Palareti; Sante Tura; Michele Baccarani
Journal:  Haematologica       Date:  2004-07       Impact factor: 9.941

Review 9.  Adverse effects of thalidomide administration in patients with neoplastic diseases.

Authors:  Meletios A Dimopoulos; Vagelis Eleutherakis-Papaiakovou
Journal:  Am J Med       Date:  2004-10-01       Impact factor: 4.965

10.  Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.

Authors:  Donna Weber; Kim Rankin; Maria Gavino; Kay Delasalle; Raymond Alexanian
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.